First Patient Dosed in Ph 1a/2a Trial of DPTX3186 in Advanced Solid Tumors, Focused on Gastric Cancer
“Reaching the clinic with a beta-catenin modulator is a defining moment for Dewpoint,” said Ameet Nathwani, M.D., Chief Executive Officer of Dewpoint Therapeutics. “This achievement reflects years of foundational science translated through a disciplined and differentiated discovery engine. It reinforces our belief that condensate modulation represents a fundamentally new and scalable way to build medicines for serious diseases.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.